Patients with Fabry disease after enzyme replacement therapy dose reduction versus treatment switch. - Wikidata - wikimedia - TriplyDB

Patients with Fabry disease after enzyme replacement therapy dose reduction versus treatment switch.

Patients with Fabry disease after enzyme replacement therapy dose reduction versus treatment switch.

http://www.wikidata.org/entity/Q37670334

about

Enzyme replacement therapy for Anderson-Fabry disease Fabry nephropathy: a review - how can we optimize the management of Fabry nephropathy?Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study.Cryptogenic stroke and small fiber neuropathy of unknown etiology in patients with alpha-galactosidase A -10T genotype.Serum-Mediated Inhibition of Enzyme Replacement Therapy in Fabry Disease.Patients with Fabry Disease after Enzyme Replacement Therapy Dose Reduction and Switch-2-Year Follow-Up.Alpha-Galactosidase A p.A143T, a non-Fabry disease-causing variant Multicenter Female Fabry Study (MFFS) - clinical survey on current treatment of females with Fabry disease.Reduction of Plasma Globotriaosylsphingosine Levels After Switching from Agalsidase Alfa to Agalsidase Beta as Enzyme Replacement Therapy for Fabry Disease Pain in Fabry Disease: Practical Recommendations for Diagnosis and Treatment.Chronic intestinal pseudo-obstruction. Did you search for lysosomal storage diseases?Switch to agalsidase alfa after shortage of agalsidase beta in Fabry disease: a systematic review and meta-analysis of the literature.Renal function predicts long-term outcome on enzyme replacement therapy in patients with Fabry disease.Changes in Ionic Conductance Signature of Nociceptive Neurons Underlying Fabry Disease Phenotype.Fabry disease and enzyme replacement therapy in classic patients with same mutation: different formulations--different outcome?Fabry disease: dose matters.Agalsidase alfa and agalsidase beta in the treatment of Fabry disease: does the dose really matter?Long-Term Dose-Dependent Agalsidase Effects on Kidney Histology in Fabry Disease.Fabry disease under enzyme replacement therapy-new insights in efficacy of different dosages.Long-term enzyme replacement therapy for Fabry disease: efficacy and unmet needs in cardiac and renal outcomes.Lucerastat, an Iminosugar for Substrate Reduction Therapy: Tolerability, Pharmacodynamics, and Pharmacokinetics in Patients With Fabry Disease on Enzyme Replacement.Reaccumulation of globotriaosylceramide in podocytes after agalsidase dose reduction in young Fabry patients.

P2860

Q26471010-8BE11BB6-D09B-4DC7-B631-EEDCE9917611 Q33645550-EF97957B-4EB9-4FE6-B934-5553C3C2B339 Q33886219-129F81A3-AF74-4686-BF7B-B5D8B1BEE0D8 Q34632438-4383E63F-4582-4188-8A68-5913B84C4687 Q36417918-CB7C169B-DCFD-49E9-A924-686D824F1814 Q36624746-56BFB5EF-24CE-4EA6-9447-13545714FF7C Q36867125-C055F49B-9048-4377-AFFE-AAE7591C4814 Q37054755-00D6387E-7E1C-4767-A6F8-C974697D77D8 Q37329223-B0B4745B-D32D-43DD-BAB3-24DA1D10371F Q37352268-96576350-5255-4CE8-8676-EE931CF55C1C Q37725235-5F1821E9-6363-4790-B7FE-31ACC007C69E Q38949519-F67DA691-072E-49A3-8FB8-5CAC6209C268 Q39344648-7B12890D-C415-49DC-AD32-88178332D229 Q41013852-529DE11E-0054-4A8C-83B6-02B92CBD63C5 Q41147394-058D765A-A652-42F8-8D0F-8D945F74699A Q42389941-2088CE09-61E5-4F71-B356-81AFDF1142E0 Q43097259-3CFB8512-CB90-457C-87B1-22A5F68F2904 Q48632125-D6D80CB7-107F-4BF4-A2A0-A3D3B3A83E94 Q49548756-6D512B37-60FE-4451-8A9A-F25DF3EA5D6B Q50793921-C8A361B3-EED0-4652-88D1-2FE541A26306 Q51842157-C69E4498-0FA7-4B6F-9417-B63F36B970FC Q53099040-88DDCB8F-5B16-48EF-BFB9-7BA3948BC6C5

P2860

Patients with Fabry disease after enzyme replacement therapy dose reduction versus treatment switch.

http://www.wikidata.org/entity/Q37670334

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 20 February 2014

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Patients with Fabry disease af ...... ction versus treatment switch.

@en

Patients with Fabry disease af ...... ction versus treatment switch.

@nl

type

label

Patients with Fabry disease af ...... ction versus treatment switch.

@en

Patients with Fabry disease af ...... ction versus treatment switch.

@nl

prefLabel

Patients with Fabry disease af ...... ction versus treatment switch.

@en

Patients with Fabry disease af ...... ction versus treatment switch.

@nl

P1433

Q37670334-09062BD3-9BB3-45EF-9DB7-3B588DA5BCA4

P1476

Q37670334-C7EEBD78-8967-4BB2-AD41-45BE8EB0B13E

P2093

Q37670334-09F9FD6A-5FB9-4A88-B9FE-2F82C31F7715

Q37670334-3B4CD34C-CB36-4582-B675-C0A5C9C2B249

Q37670334-4133731B-27C8-41C1-BA32-343FCA2824D6

Q37670334-4D91B427-3AAC-4BED-B065-0C54E2C94E39

Q37670334-63511245-77CB-46C2-A6A5-597E8F55AB0C

Q37670334-81CBDD31-8BE6-4CA9-99AC-EB403C1A3EDA

Q37670334-997DF53A-335A-4F15-80EA-4A7598D16633

Q37670334-B8AB99EF-96E4-4ED0-8339-F6928BC09F1D

Q37670334-D1761344-426E-4EE0-A252-3FD07A5EA1F9

Q37670334-D63C3B75-3D45-4465-9CCC-A6E9A8640B44

P2860

Q37670334-0042EFF0-7C36-4734-83ED-DDD92A65CC21

Q37670334-01B09D52-7B2B-4C61-B7EB-CA076B0A6CCD

Q37670334-13F7A56F-C09B-4697-85D5-277CEFCF36DC

Q37670334-1843212C-86B5-4E9D-8235-B57A50A0417A

Q37670334-1CC0B678-AD72-4E36-8E40-588B23DB55B1

Q37670334-27989968-140E-468A-A26F-8E98EF877640

Q37670334-3C08BB83-BC8E-47B6-9A07-BBF4A7490AED

Q37670334-3D721371-D16E-40CC-AA94-055E80704180

Q37670334-4EF2C3F5-9E48-473D-9B1D-872C516F2F6B

Q37670334-58CDEAC4-0EB5-4CF5-97E7-EC2D97788CA9

P304

Q37670334-C99C04E7-AD59-4F79-BCEE-FED1238350F7

P31

Q37670334-19299DD9-3A19-425C-8F86-3B0490C9652E

P356

Q37670334-1A107270-045B-4186-8158-F19F5340962E

P433

Q37670334-AA27708D-7705-45C8-B2B4-135D979A6552

P478

Q37670334-906460C1-DAF0-4A0E-8955-C6B921F160E7

P50

Q37670334-7CF506E9-53E5-4D75-98CD-85053B60ECDE

Q37670334-CBC5C408-3054-4DB4-8771-E9AF94969E60

P577

Q37670334-3D629D2B-FEEB-44C5-8B7C-214054201F4A

P698

Q37670334-AE4ABF47-2083-4671-AED7-16928C50B035

P921

Q37670334-B5D4CB48-50E0-4FF6-A900-FC6650100F4F

P932

Q37670334-A6EECCEB-C59F-49AC-8A67-96EFDBC2BF8F

P356

P1433

Journal of the American Society of Nephrology

P1476

Patients with Fabry disease af ...... uction versus treatment switch

@en

P2093

Alice Krebs

http://www.w3.org/2001/XMLSchema#string

Christoph Wanner

http://www.w3.org/2001/XMLSchema#string

Claudia Sommer

http://www.w3.org/2001/XMLSchema#string

Eva Brand

http://www.w3.org/2001/XMLSchema#string

Frank Weidemann

http://www.w3.org/2001/XMLSchema#string

Hans Guerrero González

http://www.w3.org/2001/XMLSchema#string

Jörg Stypmann

http://www.w3.org/2001/XMLSchema#string

Malte Lenders

http://www.w3.org/2001/XMLSchema#string

Markus Niemann

http://www.w3.org/2001/XMLSchema#string

Michael Schelleckes

http://www.w3.org/2001/XMLSchema#string

P2860

A new equation to estimate glomerular filtration rate

The chronic fatigue syndrome: a comprehensive approach to its definition and study. International Chronic Fatigue Syndrome Study Group

Enzyme replacement therapy with agalsidase alfa in patients with Fabry's disease: an analysis of registry data.

Enzyme replacement therapy in Fabry disease: a randomized controlled trial.

A modified score to identify and discriminate neuropathic pain: a study on the German version of the Neuropathic Pain Symptom Inventory (NPSI).

Sustained, long-term renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease.

Fabry disease, an under-recognized multisystemic disorder: expert recommendations for diagnosis, management, and enzyme replacement therapy.

Consequences of a global enzyme shortage of agalsidase beta in adult Dutch Fabry patients.

The effectiveness of long-term agalsidase alfa therapy in the treatment of Fabry nephropathy.

Effects of switching from agalsidase Beta to agalsidase alfa in 10 patients with anderson-fabry disease

P304

837-849

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1681/ASN.2013060585

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

25

http://www.w3.org/2001/XMLSchema#string

P50

Nurcan Üçeyler

Johannes Krämer

P577

2014-02-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24556354

http://www.w3.org/2001/XMLSchema#string

P921

Enzyme replacement therapy

P932

3968503

http://www.w3.org/2001/XMLSchema#string